Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Organisation › Details

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS)

NewAmsterdam (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient LDL-lowering therapy. In multiple Phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as preferred LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. *


Period Start 2024-04-01 existent
  Group NewAmsterdam Pharma (Group)
Products Industry obicetrapib (TA-8995, formerly AMG 899)
  Industry 2 drug development
Person Person Davidson, Michael (NewAmsterdam Pharma 202008 CEO before Corvidia Therapeutics)
Region Region Naarden
  Country Netherlands
  Street 2-35 Gooimeer
  City 1411 DC Naarden
    Address record changed: 2024-04-07
Basic data Employees B: 11 to 50 (2023-12-31)
  Currency USD
  Annual sales 14,090,000 (revenue, annual, consolidated (2023) 2023-12-31)
  Profit -176,937,000 (2023-12-31)
  Cash 340,450,000 (2023-12-31)
    * Document for »About Section«: NewAmsterdam Pharma Company N.V.. (4/1/24). "Press Release: NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer". Naarden & Miami, FL.
Record changed: 2024-07-19


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for NewAmsterdam Pharma (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px

» top